Treatment strategy for hepatocellular carcinoma recurrence in the transplant era : Focusing on the Japan criteria
© 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd..
PURPOSE: To clarify the Japan criteria (JC), as proposed in 2019, in order to identify the most appropriate treatment methods for hepatocellular carcinoma (HCC) recurrence and assess the feasibility of pre-living donor liver transplantation (LDLT) downstaging within these criteria.
METHODS: The subjects of this study were 169 LDLT patients with HCC recurrence. We performed univariate and multivariate analyses of the factors contributing to HCC recurrence after LDLT and clarified the post-transplant outcomes of pre-LDLT downstaging.
RESULTS: Univariate and multivariate analysis identified beyond the JC (p = 0.0018) and a neutrophil-to-lymphocyte ratio > 2.01 (p = 0.029) as independent risk factors. Patients who met the JC had significantly higher recurrence-free and overall survival rates after LDLT (p < 0.0001) than those who did not (p = 0.0002). The post-transplant outcomes of patients within the JC after downstaging were significantly better than those of patients beyond the JC (p = 0.034) and equivalent to those within the JC without downstaging.
CONCLUSION: Even for HCC recurrence, the JC could play an important role in deciding on the best treatment strategy, and downstaging within the JC had good post-transplant outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Surgery today - 54(2024), 1 vom: 31. Jan., Seite 64-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshiya, Shohei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Downstaging |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 04.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00595-023-02710-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357910850 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357910850 | ||
| 003 | DE-627 | ||
| 005 | 20240108141559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00595-023-02710-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM357910850 | ||
| 035 | |a (NLM)37289265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshiya, Shohei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment strategy for hepatocellular carcinoma recurrence in the transplant era |b Focusing on the Japan criteria |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. | ||
| 520 | |a PURPOSE: To clarify the Japan criteria (JC), as proposed in 2019, in order to identify the most appropriate treatment methods for hepatocellular carcinoma (HCC) recurrence and assess the feasibility of pre-living donor liver transplantation (LDLT) downstaging within these criteria | ||
| 520 | |a METHODS: The subjects of this study were 169 LDLT patients with HCC recurrence. We performed univariate and multivariate analyses of the factors contributing to HCC recurrence after LDLT and clarified the post-transplant outcomes of pre-LDLT downstaging | ||
| 520 | |a RESULTS: Univariate and multivariate analysis identified beyond the JC (p = 0.0018) and a neutrophil-to-lymphocyte ratio > 2.01 (p = 0.029) as independent risk factors. Patients who met the JC had significantly higher recurrence-free and overall survival rates after LDLT (p < 0.0001) than those who did not (p = 0.0002). The post-transplant outcomes of patients within the JC after downstaging were significantly better than those of patients beyond the JC (p = 0.034) and equivalent to those within the JC without downstaging | ||
| 520 | |a CONCLUSION: Even for HCC recurrence, the JC could play an important role in deciding on the best treatment strategy, and downstaging within the JC had good post-transplant outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Downstaging | |
| 650 | 4 | |a HCC recurrence | |
| 650 | 4 | |a Japan criteria | |
| 650 | 4 | |a LDLT | |
| 650 | 4 | |a Recurrent HCC | |
| 700 | 1 | |a Harada, Noboru |e verfasserin |4 aut | |
| 700 | 1 | |a Toshima, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Toshida, Katsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Kosai, Yukiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tomino, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kayashima, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshizumi, Tomoharu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery today |d 1997 |g 54(2024), 1 vom: 31. Jan., Seite 64-72 |w (DE-627)NLM012623938 |x 1436-2813 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:1 |g day:31 |g month:01 |g pages:64-72 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00595-023-02710-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 1 |b 31 |c 01 |h 64-72 | ||